Nucleis, RNAx Ink shRNA Technology Co-Marketing Deal
Nucleis, which develops custom transgenic mice, has signed a deal to co-market in vitro and in vivo shRNA validation technology with RNAx, the companies said this week.
Nucleis, RNAx Ink shRNA Technology Co-Marketing Deal
Nucleis, which develops custom transgenic mice, has signed a deal to co-market in vitro and in vivo shRNA validation technology with RNAx, the companies said this week.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.